Evaluation of the program for applied research on fertility regulation (PARFR)

External evaluation covers the period 7/81-11/85 and is based on document review and interviews with project staff and researchers. The project is helping A.I.D. to meet its goal to develop better contraceptive products for LDC use. Research subprojects are being conducted in several, high-potential areas such as: microencapsulated steroid injectables, reversible sterilization for men and women, new vaginal contraceptives, and ovulation indicators. Specific products which appear most promising include: 90-day norethindine (NET), progesterone, and testosterone injectables; the "SHUG" device for reversible vasocclusion; and the plug and clip device for tubal occlusion. However, other research, conducted in less certain areas, lacks proper planning or is of questionable value. Immunocontraception research lacks focus and cohesion (still, it is advisable to continue work in this high-risk, but also high-potential area). The potential use of anordrin is doubtful. Percutaneous vasocclusion needs careful preclinical studies, but with the right technique could be expanded. The high performance rate needed to validate the use of iodine with the FEMCEPT nonsurgical sterilization method (blockage rates on one instillation should be over 90% for LDC applications) is difficult to attain. There has been very little research overlap with other agencies. The project possesses the flexibility to respond to internal and external program needs. However, more time must be spent in focusing research work by grantees and in forward planning. This is especially important now because of the many research activities that require better technical monitoring and of the need to coordinate complex activities which have reached the product development stage. There appears to be a widening communication gap between A.I.D. and project staff. To ameliorate this, A.I.D. should clearly communicate its priorities and concerns on paper, while the project should: (1) hire 2 additional senior technical advisors and increase management oversight by the principal investigator; (2) give the Scientific Advisory Committee a greater role in planning and in research analysis; (3) document project priorities, plans, and budgets; and (4) establish an open, collegial relationship with other contraceptive research organizations, as has been done with the private sector.